Skip to content
Medical Health Aged Care

Scanfil Strengthens its Customer Portfolio in Medtech & Life Science by Signing Agreement with Liquid Instruments

Scanfil 2 mins read
MELBOURNE, Australia--BUSINESS WIRE--

Scanfil and Liquid Instruments have signed a manufacturing outsourcing agreement for Scanfil’s Melbourne plant in Australia. This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625717512/en/

This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub. Photo by Scanfil.

This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub. Photo by Scanfil.

“We’re continuing to expand our manufacturing footprint in Australia,” says Daniel Shaddock, CEO of Liquid Instruments. “Onshoring production through this partnership allows us to scale more efficiently, while deepening our investment in Australia’s technology ecosystem. Scanfil’s expertise and strong local presence make them the ideal partner for this next phase of growth.”

The collaboration will leverage Scanfil's and its subsidiary, SRXGlobal's, expertise in Medtech & Life Science. Liquid Instruments will benefit from supply chain management, scalable manufacturing, global delivery capabilities, and aftermarket services — all in Victoria, Australia.

"Liquid Instruments has developed a unique product with an interesting and complex technology that is a perfect fit for the services provided by SRXGlobal in Australia. We at Scanfil and SRXGlobal are thrilled and excited that Liquid Instruments has chosen SRXGlobal as their preferred manufacturing partner for the exciting journey ahead, and we look forward to a strong and successful partnership", states Christian Kesten, VP of Scanfil APAC.

Scanfil in brief

Scanfil plc is Europe’s largest listed provider of electronics manufacturing services (EMS), whose turnover in 2024 amounted to EUR 780 million. The company serves global sector leaders in the customer segments of Industrial, Energy & Cleantech, and Medtech & Life Science. The company’s services include design services, prototype manufacture, design for manufacturability (DFM) services, test development, supply chain and logistics services, circuit board assembly, manufacture of subsystems and components, and complex systems integration services. Scanfil’s objective is to grow customer value by improving their competitiveness and by being their primary supply chain partner and long-term manufacturing partner internationally. Scanfil’s longest-standing customer account has continued for more than 40 years. The company has global supply capabilities and eleven production facilities across four continents. www.scanfil.com


Contact details:

Further information:
Christian Kesten
Vice President, APAC region
tel. +86 512 67168867 6101
[email protected]

Pasi Hiedanpää
Director, Investor Relations and Communications
tel. +358 50 378 2228
[email protected]

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:
  • General News, Medical Health Aged Care
  • 11/07/2025
  • 07:00
La Trobe University

La Trobe researchers awarded $4.5 million in ARC Future Fellowships

LaTrobe University researchers have secured almost $4.5 million in Federal Government funding to further studies into areas such as immune cell development, Australian history and agriculture. Four researchers received an Australian Research Council (ARC) Future Fellowship 2025. The prestigious Future Fellowships support high quality research in areas of national and international benefit, including in national research priorities. Dr Lisa Mielke, from the School of Cancer Medicine, the La Trobe Institute of Molecular Science (LIMS) and the Olivia Newton-John Cancer Research Institute (ONJCRI), received $1.13 million to identify new molecules for future drug and vaccine development to improve gut health in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.